The company, a patient-centric data analytics provider, announced today (February 6) that this unparalleled amount of data enables sponsors to access patient data across more than 4,000 indications and plan more successful clinical trials. announced that it will be able to stimulate clinical development activities. With high precision.
The company says it has published the second edition of its Digital Patient Profile (DPP) catalog because of the vast data repository in the Trial Accelerator. Each DPP provides a statistical view of patient attributes to improve protocol design and accelerate adoption of digital trial arms.
The new DPPs are called relapsed/refractory follicular lymphoma, CDKL5, chronic migraine, paroxysmal migraine, stroke-acute ischemic, and acute coronary syndrome.
Rich data for sponsors
“Collating data from 100 million patients is a major milestone for Phesi. For nearly 20 years, we have collected and built a wealth of data for sponsors and clinical trial planners. ” said Dr. Gen Li, President of Phesi.
“Context is key. Phesi identifies when and where specific data was generated, by whom (researchers) and how (study designs), bringing precision, insight and certainty to clinical development. We can provide you with contextualized data to feed your team. We are committed to continuing to innovate and support our clients to make breakthroughs and bring smarter treatments to patients faster. We are working on it.”
The second edition of the Digital Patient Profile Catalog includes detailed patient data across 34 indications at both the cohort and patient level. The profile will be used by sponsors to develop digital twins and digital trial arms as part of their clinical development strategy.
The DPP also supports broader adoption of single-arm trials by helping sponsors demonstrate efficacy and safety in relevant patient cohorts. In addition to 12 oncology profiles, the catalog also covers 22 other epidemic diseases. The addition of stroke is particularly significant, as a recent analysis of all clinical trials conducted by Phesi in 2023 found that stroke is currently the third most studied disease area in the world.
Digital twins grow in popularity
“We are continually refining our methodology for creating patient profiles,” explained Jonathan Pachey, COO and Director, Phesi.
“In this way, we not only enable sponsors to make data-driven decisions in the clinical trial planning process, but also enable them to use digital twins and next-generation digital control arms. We’ve seen digital twins grow in popularity, and tools like Digital Patient Profiles are making these twins a reality.”
Fesi says the traditional data management function of collecting and interpreting patient data from clinical trials is changing. Digitized patient data can be used to enhance or replace data collected from clinical trials.
The company says Trial Accelerator brings these advances directly to users. The latest update to the platform collates data from product and disease registries, data from electronic health records, medical claims data, and data collected from nearly 100,000 dynamically updated sources, approximately 20 It represents the accumulation of years’ worth of effort. A world patent for Phesi’s method and system for analyzing and optimizing clinical trial protocols was granted by the Japan Patent Office in December 2023. This includes optimizing protocol design and minimizing avoidable protocol modifications.
